Drug Profile
S 787
Latest Information Update: 02 Aug 2002
Price :
$50
*
At a glance
- Originator Pharmacia Corporation
- Class Osteoporosis therapies
- Mechanism of Action Integrin alphaVbeta3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Postmenopausal osteoporosis
Most Recent Events
- 11 Aug 2000 Preclinical development for Postmenopausal osteoporosis in USA (Unknown route)